Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.

Introduction Cabazitaxel is a new member of the taxane group and is not crossresistant with docetaxel. In vitro it has been shown to promote tubulin assembly and also to stabilize microtubules against depolymerization as successfully as docetaxel. Cabazitaxel has recently been shown to improve survival in patients with prostate cancer who have previously been treated with docetaxel. We report the first case of cabazitaxel rechallenge in a patient with prostate cancer. He received 10 cycles of cabazitaxel initially in the TROPIC trial and then a further 7 cycles in the Early Access Programme after the publication of the TROPIC trial results. Of significance, our patient was more than 80 years of age and was also rechallenged with docetaxel and diethylstibestrol (DES).